Mayne Pharma | MYX - Ebitda



金融业
股票价格
AUD
资产
AUD 1.14B
现金及等价物
AUD 110.07M
销售成本
AUD 43.74M
流动资产
AUD 460.59M
流动负债
AUD 313.94M
债务
AUD 38.82M
EBIT
AUD -16.2M
EBITDA
AUD 20.9M
员工
450
EPS每股收益
AUD -0.15
股本和储备
AUD 454.19M
销售毛利
AUD 86.13M
债务利息支出
AUD 1.2M
贷款资金
AUD 2.66M
市值
AUD 256.07M
净收入
AUD -103.68M
营业费用
AUD 103.54M
营业利润
AUD -3.3M
普通股股本
AUD 81.25M
税前利润
AUD -14.7M
销售收入
AUD 86.5M
销售和管理费用
AUD 54.8M
股票
AUD 74.63M
贸易债权人
AUD 30.25M
应收帐款人
AUD 193.22M


Ebitda 更改 日
Ansell USD 185.8M 7M 2025-12
Avita Medical AUD -9.69M 12.21M 2025-12
Cochlear AUD 306.4M 13.5M 2025-12
CSL USD 3.13B 1.17B 2025-12
Healius AUD 74.9M 40.3M 2025-06
Integral Diagnostics AUD 46.27M 3.52M 2024-06
Medical Developments International AUD 1.78M 3.78M 2024-12
Nanosonics AUD 12.49M 1.13M 2025-12
Polynovo AUD 3.89M 100K 2025-12
Ramsay Health Care AUD 1.12B 10.6M 2025-12
ResMed USD 568.84M 21.36M 2026-03
Sigma Healthcare AUD 19.96M 5.15M 2024-07
Sonic Healthcare AUD 839.07M 51.09M 2024-12
Telix Pharmaceuticals AUD 76.49M 58.07M 2026-06